In terms of immune therapy, the treatment with the MYB-targeting TetMYB DNA vaccine showed prophylactic effects in adenomatous polyposis mouse models and overcame anti-PD-1 resistance in MYB-expressing CT26 and MC38 CRC models by increased CD8+ T-cell activation[148,149]. This evidence concerns the gene CD8A and colorectal carcinoma.